“Latest Stem Cells News”

Cancer patients in remission at a Suffolk hospital can have their own cells transplanted back to them with the use of a new piece of equipment.

The stem-cell bath defrosts frozen cells taken from people recovering from blood cancers myeloma, leukaemia and lymphoma at Ipswich Hospital.

When transplanted back to the patient following treatment the cells can help their body create new bone marrow.

The bath cuts down on the need for patients to travel to other hospitals.

The stem cells are stored at -190C in liquid nitrogen and can be kept for several years at the national blood transfusion centre in Cambridge.

They are then brought up to body temperature in just two minutes using the bath, the hospital said.

Hermione Warner-Charlick, haematology clinical nurse specialist, said: “The new bath is important because it quickly defrosts the frozen cells to give them back to the patient safely.”

British scientists have created human red blood cells from spare embryonic stem cells, a major breakthrough they claim could soon pave the way for production of synthetic ‘O-negative‘ blood for medical transfusions.

The red blood cells have been produced from stem cells from spare IVF embryos as part of a three-billion-pound project to develop an alternative source of O-negative blood, the universal donor group which can be transfused into people without fear of rejection, ‘The Independent’ reported.

In their research, the scientists used more than a 100 spare embryos left over from treatment at fertility clinics to establish several embryonic stem cell “lines“. A line, RC-7, was transformed into blood stem cells before being converted into red cells containing oxygen-carrying haemoglobin.

Prof Marc Turner, the Director of the Scottish National Blood Transfusion Service in Edinburgh and leader of the project, said that synthetic blood made on an industrial scale would overcome the problem of blood shortages and risk of transmitting new infections between donors and recipients. “We’ve proved the principle that from these embryonic stem cell lines we can generate red blood cells.

“At the end of this three-year period we would envisage generating up to one unit (a pint) of red cells from embryonic stem cells at clinical grade which fulfil all the in vitro characteristics of red cells,” Prof Turner was quoted as saying.

A breakthrough was achieved recently in the case of an 18 year old boy, a case of advanced stage of Aplastic anemia where stem cells of not one but three donors were used to treat him. This spectacular feat was achieved by the doctors at The Netaji Subhash Chandra Bose Cancer Research Institute (NSCBCRI) Kolkata.

18 year old Aman, student of class 12, fainted in school. He was diagnosed for Aplastic Anemia, a disorder where the bone marrow stops producing red blood cells and platelets. He was treated in many hospitals, but no amount of blood transfusions or ‘immuno-suppressant’ medication could help.

Dejected and depressed, Aman’s parents had almost lost their son when they happened to read a news report by chance. The doctors at NSCBCRI had successfully conducted an SCT to treat Aplastic anemia. . “I wanted to live on, and my parents saw a ray of hope, ”said Aman.
With recent advances in medicine the use of stem cells have been very effective in treating Diabetes milletus, Parkinson’s diseases, cancer, leukemia and Aplastic anemia .

They have been very effective in Bone marrow transplantation
Aman was rushed to Kolkata, but by then his condition had deteriorated. The doctors realized that only a multiple- unit SCT could save him. Overruling the risks they conducted the transplant which took three days.

With 50% chances of risk involved in a single unit SCT, the doctors had a bigger risk at hand, but a similar case conducted successfully in Seattle gave them the courage.
Today Aman Khandelwal is recouping. Thanks to the courage, confidence and competence of the doctors who treated upon him.

from http://www.beviga.com/1401/stem-cell-transplant-a-miracle/

The subject of producing artificial blood from stem cells has become a hot topic in Italy. “Italy is close to reaching the same objective announced by British researchers, on a similar timeframe,” therefore possibly in three years, “but using adult stem cells. Certainly, it is one thing to say that in three years we will begin the experimental phase, it’s another thing to speak about industrial production. It needs to be specified that the procedure to produce artificial blood is very expensive. Therefore this would be a complementary solution, which will not replace donations,” Said Welfare Undersecretary Ferruccio Fazio, shortly after an announcement of a British study, during a meeting on blood transfusion by the Health Observatory in Rome.

“I would like to calm the enthusiasm after the announcement of the British study,” said Fazio. “There are Italian research groups that are doing very advanced projects on adult stem cells to produce artificial blood. The Italian way was also chosen by the US Armed Forces,” he specified. “We are working on adult stem cells also for long-term sustainability. There is also a collaboration in place between the Mayo Clinic in America and researchers of the Superior Institute of Health (ISS),” he added. “Therefore Italy is not behind in this sector. “This is a very expensive procedure though, which will never substitute donation,” confirmed Fazio.

Furthermore, the upcoming conference of the federal government and the regions should examine a provision “that proposes financing in all of the Italian regions for umbilical cord biobanks starting in 2009. This is something,” pointed out Fazio, “that will aid in research on blood from adult stem cells”. While labs in Italy have worked for years, Giuliano Graziani, the director of the national blood centre pointed out that “the production of artificial plasma will be extremely expensive. We are not disputing the importance of donating blood. Research like the British study is ongoing throughout the world. There are important studies,” he said, “whose results are not right around the corner, and which will never replace the key role of donations”.

“In addition to unacceptable ethical implications, this research has not demonstrated anything yet,” commented geneticist Bruno Dallapiccola regarding the announcement of several British researchers, published recently on the online edition of the Independent regarding the possibility of producing blood by using embryonic stem cells.

“There are no official results yet,” said the scientist in an interview with Vatican Radio, “and none of this research has been transferred to patients. Then,” he added, “rather than reading these results in the Independent, it would be appropriate to see them published in a scientific journal with critical revisers able to judge their basis.”

In the meanwhile, the geneticists said that embryonic stem cell research aimed at curing diseases like Parkinson’s or Alzheimer’s “have not given any results yet”. A group of British researchers said that they will be able to obtain, within three years, an unlimited quantity of red blood cells from unused human embryos.

BEIJING – China is tightening regulations on the clinical use of high-risk or ethically controversial diagnostic and therapeutic technologies.
The Ministry of Health (MOH) issued a government order on Monday requiring hospitals to get approval before doing things such as artificial heart implants and homogeneous organ transplants.

The regulation goes in to effect May 1. Hospitals already using the technologies are required to report to the Ministry for verification of qualifications within six months after that date.
The MOH said its aim is to prevent abuses of those medical technologies. Previously, only some needed government approval, it said, without giving further details.

At San Timoteo di Termoli Hospital, everything is in place to begin collecting stem cells, announced the Molise Regional Health Agency (ASREM) of Termoli-Larino, adding that as agreed with the pediatrics unit of the hospital, the collection of stem cells to be used for topical use, mainly in pseudoarthrosis, will begin. Computer records and a network will be created and shared with the regional health care facilities for all transfusions. For the health agency, this is an ambitious project, which will involve the entire team from the transfusion centre, which will collaborate with Regional Executive Health President Spagnuolo in an effort to continue to improve on the services provided.